Antibody Information
General Information of This Antibody
Antibody ID | ANI0TDYTK |
|||||
---|---|---|---|---|---|---|
Antibody Name | Anti-FGFR2 mAb 12433 |
|||||
Antibody Type | Monoclonal antibody (mAb) |
|||||
Antibody Subtype | Humanized IgG1-kappa |
|||||
Antigen Name | Fibroblast growth factor receptor 2 (FGFR2) |
Antigen Info |
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Anti-FGFR2 mAb-12433 SMCC-DM1 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 44.97% (Day 38) | Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
The total injection volume containing cells in suspension was 200 ul. Mice were enrolled in the first study eight days post implantation with average tumor volume of 208.4 mm3. After being randomly assigned to one of nine groups (n =8/group), mice were administered PBS or a single 10 mg/kg intravenous (i.v,) injection of one antibody drug conjugates.
Click to Show/Hide
|
||||
In Vivo Model | MFM223 CDX model | ||||
In Vitro Model | Breast carcinoma | MFM-223 cells | CVCL_1408 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 91.03% (Day 33) | Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
The total injection volume containing cells in suspension was 200 ul. Mice were enrolled in the first study eight days post implantation with average tumor volume of 192.9 mm3. After being randomly assigned to one of nine groups (n =8/group), mice were administered PBS or a single 3 mg/kg intravenous (i.v,) injection of one antibody drug conjugates.
Click to Show/Hide
|
||||
In Vivo Model | SNU-16 CDX model | ||||
In Vitro Model | Gastric adenocarcinoma | SNU-16 cells | CVCL_0076 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.69% (Day 31) | Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
The total injection volume containing cells in suspension was 200 ul. Mice were enrolled in the first study eight days post implantation with average tumor volume of 192.9 mm3. After being randomly assigned to one of nine groups (n =8/group), mice were administered PBS or a single 3 mg/kg intravenous (i.v,) injection of one antibody drug conjugates.
Click to Show/Hide
|
||||
In Vivo Model | SNU-16 CDX model | ||||
In Vitro Model | Gastric adenocarcinoma | SNU-16 cells | CVCL_0076 | ||
Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 35) | Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
The total injection volume containing cells in suspension was 200 ul. Mice were enrolled in the first study eight days post implantation with average tumor volume of 233 mm3. After being randomly assigned to one of nine groups (n =8/group), mice were administered PBS or a single 15 mg/kg intravenous (i.v,) injection of one antibody drug conjugates.
Click to Show/Hide
|
||||
In Vivo Model | SNU-16 CDX model | ||||
In Vitro Model | Gastric adenocarcinoma | SNU-16 cells | CVCL_0076 |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.29 nM
|
Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.
Click to Show/Hide
|
||||
In Vitro Model | Breast carcinoma | SUM52PE cells | CVCL_3425 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | < 3.00 nM | Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.
Click to Show/Hide
|
||||
In Vitro Model | Gastric adenocarcinoma | SNU-16 cells | CVCL_0076 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | < 3.00 nM | Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.
Click to Show/Hide
|
||||
In Vitro Model | Down syndrome | KATO III cells | CVCL_0371 | ||
Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
24.00 nM
|
Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.
Click to Show/Hide
|
||||
In Vitro Model | Breast carcinoma | MFM-223 cells | CVCL_1408 | ||
Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 30.00 nM | Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.
Click to Show/Hide
|
||||
In Vitro Model | Cecum adenocarcinoma | NCI-H716 cells | CVCL_1581 | ||
Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 30.00 nM | Negative FGFR2 expression (FGFR2-) | ||
Method Description |
Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.
Click to Show/Hide
|
||||
In Vitro Model | Gastric carcinoma | NUGC-3 cells | CVCL_1612 |
Anti-FGFR2 mAb-12433 SPDB-DM4 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 35) | Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
The total injection volume containing cells in suspension was 200 ul. Mice were enrolled in the first study eight days post implantation with average tumor volume of 233 mm3. After being randomly assigned to one of nine groups (n =8/group), mice were administered PBS or a single 5 mg/kg intravenous (i.v,) injection of one antibody drug conjugates.
Click to Show/Hide
|
||||
In Vivo Model | SNU-16 CDX model | ||||
In Vitro Model | Gastric adenocarcinoma | SNU-16 cells | CVCL_0076 |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.80 nM
|
Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.
Click to Show/Hide
|
||||
In Vitro Model | Gastric adenocarcinoma | SNU-16 cells | CVCL_0076 |
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.